Uses of t cell engaging proteins in the treatment of cancer

A body-weight-tailored dosing regimen for T cell engaging proteins targeting CD3 and DLL3 in neuroendocrine neoplasms allows for higher, safer doses, overcoming treatment limitations and side effects in current therapies.

WO2024240635A1PCT designated stage expired Publication Date: 2024-11-28BOEHRINGER INGELHEIM INT GMBH
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/063678
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-17
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current treatments for neuroendocrine neoplasms, such as small cell lung cancer and glioma, are ineffective in achieving long-term remission and are associated with significant side effects like cytokine release syndrome, limiting the dosage of T cell engaging proteins that can be administered.

Method used

A dosing regimen for T cell engaging proteins that specifically bind to CD3 and DLL3, involving a step-in cycle with initial, elevated, and further doses tailored to the patient's body weight, allowing for higher doses while minimizing adverse effects like cytokine release syndrome.

Benefits of technology

This approach enables unprecedented high doses of T cell engaging proteins to be administered safely, reducing side effects and achieving clinical responses while avoiding severe adverse events.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000048_0001
    Figure IMGF000048_0001
  • Figure IMGF000049_0001
    Figure IMGF000049_0001
  • Figure IMGF000054_0001
    Figure IMGF000054_0001
Patent Text Reader

Abstract

The invention generally relates to the treatment of cancer by using DLL3 / CD3 binding proteins In particular, the present invention relates to uses and methods of using DLL3 / CD3 binding proteins in a dosage and administration regimen for the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors

    WO1990005144A1

  • Cytotoxicity-inducing therapeutic agent

    WO2019131988A1

  • DLL3-CD3 bispecific antibodies

    WO2019234220A1

  • DLL3 binding proteins and methods of use

    WO2020069028A1

  • DLL3-targeting multispecific antigen-binding molecules and uses thereof

    WO2021200898A1